Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors
- Harvard Medical School, Boston, MA (United States)
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Washington Univ. School of Medicine, St. Louis, MO (United States)
- Los Alamos National Laboratory
- Harvard Medical School, Boston, MA (United States); Ragon Inst. of MGH, Boston, MA (United States)
Adenovirus vectors are widely used as vaccine candidates for a variety of pathogens, including HIV-1. To date, human and chimpanzee adenoviruses have been explored in detail as vaccine vectors. Furthermore, the phylogeny of human and chimpanzee adenoviruses is overlapping, and preexisting humoral and cellular immunity to both are exhibited in human populations worldwide. More distantly related adenoviruses may therefore offer advantages as vaccine vectors. We describe the primary isolation and vectorization of three novel adenoviruses from rhesus monkeys. The seroprevalence of these novel rhesus monkey adenovirus vectors was extremely low in sub-Saharan Africa human populations, and these vectors proved to have immunogenicity comparable to that of human and chimpanzee adenovirus vaccine vectors in mice. These rhesus monkey adenoviruses phylogenetically clustered with the poorly described adenovirus species G and robustly stimulated innate immune responses. These novel adenoviruses represent a new class of candidate vaccine vectors.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE
- Grant/Contract Number:
- AC52-06NA25396
- OSTI ID:
- 1235731
- Report Number(s):
- LA-UR--14-28201
- Journal Information:
- Journal of Virology, Journal Name: Journal of Virology Journal Issue: 3 Vol. 89; ISSN 0022-538X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Protection of non-human primates against rabies with an adenovirus recombinant vaccine
An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity
Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques
Journal Article
·
Fri Feb 14 23:00:00 EST 2014
· Virology
·
OSTI ID:22435016
An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity
Journal Article
·
Mon Feb 11 19:00:00 EST 2013
· Virology Journal
·
OSTI ID:1626615
Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques
Journal Article
·
Mon Jan 19 23:00:00 EST 2009
· Virology
·
OSTI ID:21182798